Avalo Therapeutics (NASDAQ:AVTX) Price Target Raised to $40.00 at HC Wainwright

Avalo Therapeutics (NASDAQ:AVTX) had its price objective upped by HC Wainwright from $25.00 to $40.00 in a research report report published on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other equities analysts have also recently commented on AVTX. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. BTIG Research restated a “buy” rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Finally, Guggenheim started coverage on Avalo Therapeutics in a research note on Monday, February 2nd. They set a “buy” rating and a $50.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Avalo Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $42.25.

Avalo Therapeutics Trading Up 3.7%

NASDAQ AVTX opened at $13.95 on Wednesday. The firm has a market capitalization of $317.92 million, a P/E ratio of -2.43 and a beta of 0.84. The firm’s fifty day moving average price is $15.53 and its two-hundred day moving average price is $15.77. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter. On average, research analysts anticipate that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Insider Activity at Avalo Therapeutics

In related news, insider Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the sale, the insider owned 3,622 shares of the company’s stock, valued at approximately $58,495.30. The trade was a 87.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.03% of the company’s stock.

Institutional Investors Weigh In On Avalo Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Orbimed Advisors LLC boosted its holdings in shares of Avalo Therapeutics by 39.5% during the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock worth $17,150,000 after acquiring an additional 382,300 shares during the period. Nantahala Capital Management LLC increased its stake in shares of Avalo Therapeutics by 24.1% during the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after purchasing an additional 240,000 shares during the period. Affinity Asset Advisors LLC lifted its holdings in Avalo Therapeutics by 4.5% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company’s stock worth $19,087,000 after purchasing an additional 44,837 shares during the last quarter. Caligan Partners LP lifted its holdings in Avalo Therapeutics by 5.8% during the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after purchasing an additional 48,200 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in Avalo Therapeutics in the 3rd quarter valued at $10,390,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.